Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

Pfizer Chairman and CEO Albert Bourla did not mince his words at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on Monday regarding the controversial positions that Robert F.

Pfizer PFE-2.36%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 1.12%increase; green up pointing triangle for 2.50 billion ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello everyone! This is Allison DeAngelis, Jason Mast, Angus Chen, and ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million ...

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...